RE: Flowflex, Orient Gene, etc13 Dec 2021 18:18
The gripe I have for the ceo is the tone he used in presenations regarding investor updates. As if avacta have been unfairly hassled for updates.
The fact is they gave almost a running commentary in the development of the lft and bandied around volume of 30m tests a month. Hit none of there time lines, completely changed tack of lft development without updating the market.
Im not surprised they have had or are having a lot of questions.